Tuberculosis is among the top 10 causes of death worldwide.The WHO clearly proposed that drug-resistant tuberculosis is one of the three major challenge in tuberculosis prevention and control .The book consists of detection of drug-resistant TB and its epidemics, laboratory examination for drug-resistant tubercle bacillus, pathogenic mechanism of drug-resistant TB and its diagnosis, differential diagnosis, treatment, prevention and prognosis of drug-resistant pulmonary TB. This book also focuses on the information of classic cases of drug-resistant TB, including mono-drug-resistant (including Rifampicin resistance, etc.), multidrug-resistant, poly-drug-resistant, extensive-drug-resistant (pre-extensive-drug-resistant), drug-resistant bronchial TB, and pediatric drug-resistant, as well as AIDS complicated with drug-resistant TB, and diagnosis and treatment of drug-resistant cervical TB lymphadenitis. The book also provided a comprehensive description and in-depth analysis for each selected case and a systematic explanation for latest cutting-edge issues, such as dynamic changes in images during the treatment of drug-resistant TB as well as the research and application of artificial intelligence in diagnosing drug-resistant TB, to further inspire our readers. This is a useful book to refer to for respiratory physicians, radiologists, and clinicians in preventive medicine, as well as government officials working in health policies.
Pu-Xuan Lu is a Chief Medical Specialist of Shenzhen Center for Chronic Disease Control，Shenzhen Institute of Pulmonology; first-level chief physician of The Third People's Hospital of Shenzhen; a professor and graduate supervisor of Guangdong Medical University.
His research fields include diagnostic imaging and differential diagnosis of emerging infectious diseases, such as SARS, MERS, AIDS, human infected avian influenza, tuberculosis, hepatitis, and other infectious diseases as well as clinical and basic sciences of emerging infectious diseases.
Professor Lu has edited or co-edited more than 20 academic treatise.
Diagnostic Imaging of Emerging Infectious Diseases has been published by Springer in November 2015, which obtained national key award for book output in May 2017 by the General Administration of News and Publishing, China.In 2020, he co-edited
Tuberculosis Control in Migrating Population in Springer, and won the third Springer Nature: China New Development Award in September 2021.
Hongzhou Lu, M.D., Ph.D., the director of Shenzhen Third People's Hospital, a world-renowned scholar of infectious diseases, World's Top 2% Scientists in 2021 (Stanford University), winner of the Charpak Dubousset Prize of the French National Academy of Medicine, fellow of the American Academy of Microbiology
Prof. Lu has long been dedicated to the basic research and clinical practice of infectious diseases. During the influenza A (H1N1, H7N9) and COVID-19 pandemics, he led the early treatment efforts and pioneered clinical and basic research on related diseases in Shanghai, making essential contributions to the prevention of disease epidemics in China. Professor Lu's work has been supported by the Bill & Melinda Gates Foundation, and the National Institutes of Health. He has published more than 500 research papers in international journals, including Nature, New England Journal of Medicine, and Cell Research et al.
Yong-xiang Yi, MD, Vice President of Nanjing Drum Tower Hospital. Distinguish Professor, Ph.D Supervisor of Nanjing University of Chinese medicine. National Excellent Hospital President. Experts rewarded special government allowances from the State Council. Vice Chairman of Infectious Disease Hospital of China Hospital Association.Vice Chairman of the Liver Disease Committee of the Chinese Association of Research Hospitals and Leader of the Liver Cancer Group. Chairman of infectious disease hospital of Jiangsu Hospital Association. Chairman of the Infectious Diseases of Jiangsu Association of Traditional Chinese Medicine.
He has been engaged in general surgery for more than 30 years, and has long been committed to the research of various complicate liver disease, gallbladder and pancreatic tumors, intestinal microbiota. He has conducted multiple national, provincial and municipal scientific research projects, published more than 60 SCI papers, written 7 professional books, and published 2 international patents.
